Design Therapeutics

DSGN · NASDAQ

$11.10+$0.46 (+4.32%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $10.64

DSGN analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $21.42 (+93.0% upside)

Low: $20.20
Now: $11.10
High: $23.10

Upgrades and downgrades

The latest rating actions, newest first

DSGN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 2, 2026	Initiates	Overweight	$26.00	0%
Oppenheimer	May 4, 2026	Maintains	Outperform	$18.00 → $21.00	22%
Jefferies	Mar 16, 2026	Initiates	Buy	$15.00	58%
RBC Capital	Mar 10, 2026	Maintains	Outperform	$13.00 → $14.00	49%
Oppenheimer	Jan 7, 2026	Initiates	Outperform	$18.00	82%
Leerink Partners	Dec 3, 2025	Upgrade	Market Perform → Outperform	$7.00 → $14.00	34%
RBC Capital	Nov 20, 2025	Upgrade	Sector Perform → Outperform	$6.00 → $13.00	49%
RBC Capital	Nov 6, 2025	Maintains	Sector Perform	$5.00 → $6.00	49%

The case for and against

Updated Nov 28, 2024

Bull case

Design Therapeutics Inc. is experiencing promising advancements in its clinical-stage programs, particularly with the new formulation of DT-216 for Friedreich ataxia (FA), which has shown improvements in both tolerability and pharmacokinetics. The recent clearance of the DT-168 IND for Fuchs endothelial corneal dystrophy (FECD) by the FDA signifies regulatory progress that could enhance the company's development pipeline. These developments suggest a positive momentum for Design Therapeutics, as advancements in safety profiles and early-stage data may indicate future growth potential and value enhancement for investors.

Bear case

Design Therapeutics Inc faces significant downside risks stemming from potential setbacks in its product candidate developments, particularly with DT-216 and its GeneTACTM programs targeting Friedreich ataxia and Fuchs endothelial corneal dystrophy. The company's recent earnings report highlighted a need for operational expense reductions, indicating a potential misalignment of its cash runway with strategic priorities, as evidenced by an $13.3 million R&D expenditure that fell short of expectations. Furthermore, multiple regulatory and clinical risks could hinder the company's progress, including the possibility of unexpected safety signals, failure to demonstrate clinical efficacy, and challenges in achieving necessary regulatory approvals and commercialization.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.